|
Liquid-hydrogel Hybrid Microfluidic Device
Application
Measurement device for detecting of single-cell dynamics under environment perturbations or drug treatment.
Key Benefits
Fast determination of drug sensitivity.
Long-term continuous cell-fate tracking.
Time-lapse analysis of cell proliferation.
Cell community analysis: intra-species interactions, inter-species interactions.
Market...
Published: 12/20/2022
Contributor(s): Kyle Allison, Xin Fang, Devina Puri
|
|
Know@Home: Mobile App for Promoting the Prevention and Treatment of HIV
Application
A healthcare oriented mobile app for promoting the prevention and treatment of HIV.
Key Benefits
User-friendly application.
Contains educational information, assessments, locators, testing plans and reminders regarding sexual health and STI testing.
Market Summary
Human immunodeficiency virus (HIV) and acquired immunodeficiency...
Published: 12/20/2022
Contributor(s): Patrick Sullivan, Robert Stephenson
|
|
SARS-CoV-2 Neutralizing Human Monoclonal Antibodies
Application
Monoclonal antibodies to SARS-CoV2 for use in COVID-19 diagnostics and therapeutics.
Key Benefits
Demonstrably neutralizing, important for therapeutic mAbs.
Most bind both RBG and stalk portion of spike protein, useful in case SARS-CoV2 strains develop variation in RBD.
Market Summary
Coronavirus (COVID-19) is an infectious...
Published: 10/28/2022
Contributor(s): Jens Wrammert, Carl Davis, Mehul Suthar, Robert Kauffman
|
|
BG505 SOSIP Vaccine Elicited Neutralizing Monoclonal Antibodies for HIV
Application
ELISA
Western Blot
Immunohistochemistry
Specficity
HIV-1 BG505 Env protein (clone name: YRK01, YRK02).
Subtype
Monoclonal antibody.
Immunogen
HIV-1 BG505 SOSIP Env trimer.
Technical Summary
HIV-1 envelope glycoprotein (Env) is a membrane protein complex involved in receptor recognition and viral fusion with CD4+ T cells...
Published: 9/29/2022
Contributor(s): Cynthia Derdeyn, Tysheena Charles
|
|
Treatment of Antimicrobial Resistance Infections
Application
Novel compounds and peptides for the treatment of antibiotic-resistant infections.
Key Benefits
Novel mechanism of action that facilitates that killing of GAS in skin keratinocytes.
Novel drugs may overcome bacterial resistance to commonly used FDA-approved modifications.
Potentially synergy in combination with existing treatments.
Possible...
Published: 9/29/2022
Contributor(s): Christopher LaRock, Doris LaRock
|
|
Combination of Tetrahydrobiopterin and Arginine/ ± Arginase Inhibitors for the Treatment of COVID-19
Application
A novel drug combination to address acute arginine/BH4 dysregulation that develops with COVID-19 and MIS-C infection.
Key Benefits
Potential to improve outcomes of those infected with COVID-19 with few side effects.
Repurposing opportunity with the combination of two approved drugs (tetrahydrobiopterin and arginine).
Addresses...
Published: 10/28/2022
Contributor(s): Claudia Morris, Louann Brown
|
|
Small Molecule Inhibitors for the Treatment of COVID-19 Infection
Application
Small molecule therapy to treat patients infected with COVID-19 virus.
Key Benefits
Current FDA-approved therapeutic can be repurposed to fight COVID-19 infection.
Treatment option for infected COVID-19 patients.
Market Summary
Coronavirus (COVID-19) is an infectious disease that causes severe acute respiratory syndrome coronavirus...
Published: 12/20/2022
Contributor(s): Jack Arbiser, Martijn van Hemert, Melissa Thaler
|
|
Serological Test for SARS-CoV-2
Application
Clinical assay for detecting SARS-CoV-2 neutralizing antibodies.
Key Benefits
Highly specific and sensitive.
Fewer false positives than commercially available tests.
Market Summary
SARS-CoV-2 is currently causing a devastating pandemic and there is a pressing need to understand the dynamics, specificity, and neutralizing...
Published: 1/10/2023
Contributor(s): Rafi Ahmed, Mehul Suthar, John Roback, Jens Wrammert, Robert Kauffman
|
|
A New Method to Detect and Tackle Antibiotic Heteroresistance
Application
A method to detect heteroresistance to antibiotics in bacteria.
Key Benefits
Significantly faster than commercially available options.
Aside from the interferometer itself, no specialized reagents are required.
Inexpensive to use.
Market Summary
Antibiotic resistance is a significant threat to public health. Rapid and sensitive...
Published: 1/10/2023
Contributor(s): David Weiss, Peter Yunker, David Hufnagel, Arben (Ben) Kalziqi
|
|
Frog Skin Peptides for Treatment of Human Influenza Viruses
Application
A therapeutic peptide that treats Influenza A virus
Key Benefits
New method of action compared to antiviral drugs currently in use.
Therapeutic peptide is virucidal against drug resistant strains.
Market Summary
Worldwide seasonal influenza epidemics can impact 5 – 15% of the population. The occurrence of vaccine mismatch...
Published: 9/29/2022
Contributor(s): Joshy Jacob, David Holthausen, Song Lee, Sanil George
|